WO2023066856A1 - Injektionsbehälter, befüllt mit einer wasserhaltigen, injizierbaren zusammensetzung - Google Patents
Injektionsbehälter, befüllt mit einer wasserhaltigen, injizierbaren zusammensetzung Download PDFInfo
- Publication number
- WO2023066856A1 WO2023066856A1 PCT/EP2022/078815 EP2022078815W WO2023066856A1 WO 2023066856 A1 WO2023066856 A1 WO 2023066856A1 EP 2022078815 W EP2022078815 W EP 2022078815W WO 2023066856 A1 WO2023066856 A1 WO 2023066856A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- injection container
- container according
- hyaluronic acid
- salt
- Prior art date
Links
- 238000002347 injection Methods 0.000 title claims abstract description 52
- 239000007924 injection Substances 0.000 title claims abstract description 52
- 239000007972 injectable composition Substances 0.000 title claims abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract description 101
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 33
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 32
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 31
- 235000005152 nicotinamide Nutrition 0.000 claims abstract description 21
- 239000011570 nicotinamide Substances 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 229960003966 nicotinamide Drugs 0.000 claims abstract description 13
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 9
- 201000008482 osteoarthritis Diseases 0.000 claims description 9
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 8
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 8
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 8
- 230000002917 arthritic effect Effects 0.000 claims description 7
- 239000011521 glass Substances 0.000 claims description 7
- 210000001503 joint Anatomy 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 239000003708 ampul Substances 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 159000000011 group IA salts Chemical class 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000003932 viscosupplement Substances 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- -1 alkali metal salt Chemical class 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000003011 chondroprotective effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/505—Stabilizers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/3129—Syringe barrels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/24—Materials or treatment for tissue regeneration for joint reconstruction
Definitions
- the invention relates to an injection container filled with a water-containing, injectable composition, in particular for intra-articular application, the composition containing at least one salt of hyaluronic acid.
- Arthrosis is a degenerative joint disease and is currently the most common joint disease worldwide. Due to the increasing average age of the population, larger and larger sections of the population are affected. In joints affected by arthrosis, the layer of cartilage that is arranged between the joint bones and serves as a buffer shrinks, so that the distance between the joint bones becomes increasingly smaller and the load on the joint increases under stress, until finally the joint bones come into direct contact with one another stand. As a result of arthrosis, the joint wears out more and more when it is put under strain, which is associated with severe pain.
- compositions containing hyaluronic acid and/or its salts are injected into the space in a joint affected by arthrosis applied, which is also referred to as viscosupplementation.
- Hyaluronic acid is a polysaccharide formed by several disaccharide repeat units each having D-glucuronic acid and N-acetyl-D-glucosamine.
- hyaluronic acid is also contained in particular in the natural synovial fluid, which is also known as synvovial fluid.
- the application of hyaluronic acid and/or its salts therefore causes joint-lubricating, anti-inflammatory and chondroprotective effects that contribute to alleviating arthritic symptoms.
- the compositions used in this context are also referred to as viscoelastics.
- compositions containing hyaluronic acid and/or its salt is determined in particular by the stability of the hyaluronic acid and/or its salts.
- hyaluronic acid and/or its salts are broken down by hydrolysis of the glycosidic bonds.
- thermodynamics Eur. Polym. J., Vol. 32, No. 8, 1996, pp. 1011 to 1014
- a lower number of hyaluronic acid chains corresponds to a reduced viscosity of the composition and causes an increasingly lower effectiveness of the administered composition, in particular an increasingly lower protective effect on the joint affected by arthrosis.
- the shelf life of the known compositions, and thus also that of the injection container filled with them is severely limited.
- a further disadvantage when administering the known compositions is that they first have to be filled into the application container, which is a laborious process. This is not only associated with additional expenditure of time but is also error-prone, since after the application container has been filled a visual check of the filled composition must always be carried out. Finally, there is also the risk that the composition will be contaminated during filling.
- the object of the invention is achieved by an injection container of the type mentioned at the outset that is filled with the composition, the composition containing nicotinic acid and/or nicotinamide.
- the invention is based on the basic idea that the nicotinic acid and/or nicotinamide contained in the composition of the injection container according to the invention serves as a stabilizing component, which slows down the degradation of the physiologically active hyaluronic acid, so that the durability of the composition of the injection container according to the invention is increased is significantly extended compared to the known compositions. This also extends the durability of the injection container.
- the injection container according to the invention can be used directly and immediately. Since the injection container does not have to be drawn up or transferred before use, there is also a need for a visual inspection of the injection container, especially its composition. In addition to improved durability, the applicability of the injection container according to the invention filled with the composition is also improved.
- composition of the injection container according to the invention can be in the form of a gel for easy application and/or can be sterilized.
- the composition of the injection container according to the invention for medical use contains at least one alkali metal salt of hyaluronic acid, in particular sodium hyaluronate.
- the composition preferably contains hyaluronic acid and/or salts thereof in a total mass concentration of 10 mg/ml to 30 mg/ml, in particular 15 mg/ml to 25 mg/ml, most preferably around 25 mg/ml, with the concentration data can relate to the combination of hyaluronic acid and its salts.
- the hyaluronic acid and/or its salts in the composition can have a total molecular weight of between 100 kDa and 3 MDa, with 1 Da corresponding to an atomic mass unit u.
- the composition preferably contains nicotinic acid and/or nicotinamide in a total mass concentration of from 1 mg/ml to 30 mg/ml, in particular from 1 mg/ml to 25 mg/ml, most preferably from 5 mg/ml to 25 mg/ml to slow down the breakdown of hyaluronic acid and/or its salt.
- the composition contains nicotinic acid and/or nicotinamide in a mass concentration of approximately 15 mg/ml.
- the concentration rat ion information may relate to the combination of nicotinic acid and nicotinamide.
- the composition contains a buffer solution, in particular containing phosphate, in order to stabilize the pH of the composition, preferably at a pH of about 7.
- the composition has an osmolarity of 270 mOsm/l to 450 mOsm/l.
- the composition is free from crosslinked hyaluronic acid and/or hyaluronic acid salt polymers.
- the injection container is preferably at least one member of the following group: syringe, syringe barrel, vial, ampoule.
- the injection container is designed as a component of a syringe or is designed as a syringe in order to improve the durability of the composition of the injection container and also its applicability.
- a further development of the invention can provide that the injection container is made of glass or plastic for reasons of hygiene. Provision is particularly preferably made for the injection container to be a glass syringe.
- composition and/or the interior of the injection container in particular its inner wall
- the composition and the interior of the injection container, in particular its inner wall are particularly preferably sterilized in order to form a sterile double barrier, so that the durability and usability of the injection container is further improved. Along with this, the safety for the user and for the patient is also increased.
- a glass syringe can be filled with the composition, the syringe being designed in particular as a disposable syringe for hygiene purposes.
- the syringe can be designed as a reusable syringe in order to enable the application of several doses of the composition.
- the injection container according to the invention filled with the composition can be intended for use in a method for treating arthrosis, in particular for treating an arthritic joint, the composition being injected in particular intra-articularly into the arthritic joint.
- Fig. 1 measured viscosity values for both compositions over time in a ty diagram.
- Tab. 1 shows the components of a composition A known from the prior art, which is used as a viscosupplement composition, in particular for the treatment of arthritic complaints.
- the left column, titled I gives the chemical formulas of the ingredients of composition A.
- the middle column of Table 1 with the title M contains the names of the ingredients and their numbers in the European Pharmacopoeia.
- the right-hand column entitled c contains the concentration data of the ingredients of composition A in g/l.
- Composition A consequently contains in particular sodium hyaluronate, the sodium salt of hyaluronic acid, in a mass concentration of 25.0 g/l.
- the required amount of water for injection purposes abbreviated as "H 2 O" in FIG. 1, is provided to achieve the desired volume of composition A, here 1 liter.
- Tab. 2 shows the components of a composition B, with which an injection container according to the invention (not shown) is filled, as a viscosupplement composition similar to the representation in Tab their concentrations of composition A, composition B of the injection container according to the invention additionally containing nicotinamide, the amide of nicotinic acid, which is also referred to as niacinamide, in a mass concentration of 15 g/l.
- composition B contains the amount of water for injections required to reach the desired volume.
- the hyaluronic acid or their salt When using the known compositions for the treatment of arthritic complaints, the hyaluronic acid or their salt, the physiological active substance.
- the degradation of the hyaluronic acid or its salt as a component of the composition takes place through hydrolysis of the glycosidic bonds as a result of the water contained in the composition, which impairs the storage time of hyaluronic acid-containing compositions.
- the degradation of the hyaluronic acid or its salt is expressed physically in an increasingly lower viscosity of the composition, so that determining the viscosity of a composition can provide information about the amount of hyaluronic acid or its salt still present in the composition.
- composition B of the injection container according to the invention which is more precisely contained in a mass concentration of 15 g/l
- the viscosity of composition B was measured over a period of 45 days and compared to the viscosity readings for Composition A, which does not contain any nicotinamide.
- 2 liters were provided for each of the two compositions A, B, the pH of both compositions being approximately 7 in each case.
- composition B To determine the long-term effects of nicotinamide on the sodium hyaluronate in composition B, both compositions A, B were stored at a temperature of 50 °C for the duration of the measurements, whereas a temperature of ca. 25°C can be assumed. It is known from research results on the temperature-dependent degradation of sodium hyaluronate that sodium hyaluronate is degraded 34 times faster at a pH value of 7 and at a temperature of 50°C than at 25°C.
- compositions A and B of the injection container according to the invention were stored for the duration of the viscosity measurements at a temperature of 50° for 45 days, which corresponds to 1.575 days, ie about 76.5 months, with regular storage at a temperature of 25° C.
- the viscosity of compositions A and B was measured repeatedly over the entire period of 45 days.
- Fig. 1 shows the results of the viscosity measurements for the composition A known from the prior art and for the composition B of the injection container according to the invention, the results being entered in a tY diagram, according to which the t-axis of the time and the y-axis Axis correspond to the values for the viscosity ⁇ .
- the straight lines drawn correspond to the measured viscosity values for compositions A and B.
- linear regressions assigned to the measurement results were determined, the values of which are interpolated as points in FIG. 1 are shown.
- the parameters of the linear regressions are shown in Fig. 1 entered.
- the quality parameter R 2 determined by linear regression is 0.998 for the known composition A and 0.996 for the composition B, which indicates a good linear fit in both cases.
- A, B corresponds to .
- the known composition A has a viscosity of about 205 P and the composition B has a viscosity ⁇ of about 300 P.
- test results show that with the same boundary conditions, the viscosity ⁇ of the known composition A according to Tab. 1 decreases faster than the viscosity ⁇ of the composition B of the injection container according to the invention according to Tab. 2 . Due to the already described relationship between the viscosity ⁇ and the breakdown of hyaluronic acid, the test results thus show that the breakdown of sodium hyaluronate in composition B of the injection container according to the invention takes place more slowly than in the known composition A. From this it follows in turn that the nicotinamide present in the composition B significantly inhibits the breakdown of hyaluronic acid and the shelf life of the composition B of the injection container according to the invention, in particular compared to the known composition A, is extended. This also applies to the shelf life of a composition B located in a glass syringe as an injection container.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22808622.9A EP4392042A1 (de) | 2021-10-18 | 2022-10-17 | Injektionsbehälter, befüllt mit einer wasserhaltigen, injizierbaren zusammensetzung |
CA3233718A CA3233718A1 (en) | 2021-10-18 | 2022-10-17 | Injection container filled with an aqueous injectable composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102021126946.6A DE102021126946A1 (de) | 2021-10-18 | 2021-10-18 | Wasserhaltige, injizierbare Zusammensetzung und mit der Zusammensetzung gefüllte Spritze |
DE102021126946.6 | 2021-10-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023066856A1 true WO2023066856A1 (de) | 2023-04-27 |
Family
ID=84360494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2022/078815 WO2023066856A1 (de) | 2021-10-18 | 2022-10-17 | Injektionsbehälter, befüllt mit einer wasserhaltigen, injizierbaren zusammensetzung |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP4392042A1 (de) |
CA (1) | CA3233718A1 (de) |
DE (1) | DE102021126946A1 (de) |
WO (1) | WO2023066856A1 (de) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120237610A1 (en) * | 2009-12-18 | 2012-09-20 | Jean-Noel Thorel | Injectable compositions for intra-articular use combining a viscosupplementation agent and a fibroblast growth medium |
WO2014026161A1 (en) * | 2012-08-10 | 2014-02-13 | Aquavit Pharmaceuticals, Inc. | Vitamin supplement compositions for injection |
CN112294668A (zh) * | 2020-06-30 | 2021-02-02 | 西安博和医疗科技有限公司 | 透明质酸注射液 |
CN113368027A (zh) * | 2018-09-30 | 2021-09-10 | 白晋 | 一种自体胶原蛋白水光针及其制备方法 |
WO2022090897A1 (en) * | 2020-10-26 | 2022-05-05 | Innate S.R.L. | Injectable composition and use of said composition |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010027203A1 (en) | 2000-03-21 | 2001-10-04 | Weidner Morten Sloth | Chemical complex comprising a pyridine carboxy derivative and an H2 histamine receptor antagonist |
US20160074519A1 (en) | 2013-04-25 | 2016-03-17 | Aluron Biopharma Inc. | Crosslinked hyaluronic acid compositions |
-
2021
- 2021-10-18 DE DE102021126946.6A patent/DE102021126946A1/de active Pending
-
2022
- 2022-10-17 WO PCT/EP2022/078815 patent/WO2023066856A1/de active Application Filing
- 2022-10-17 CA CA3233718A patent/CA3233718A1/en active Pending
- 2022-10-17 EP EP22808622.9A patent/EP4392042A1/de active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120237610A1 (en) * | 2009-12-18 | 2012-09-20 | Jean-Noel Thorel | Injectable compositions for intra-articular use combining a viscosupplementation agent and a fibroblast growth medium |
WO2014026161A1 (en) * | 2012-08-10 | 2014-02-13 | Aquavit Pharmaceuticals, Inc. | Vitamin supplement compositions for injection |
CN113368027A (zh) * | 2018-09-30 | 2021-09-10 | 白晋 | 一种自体胶原蛋白水光针及其制备方法 |
CN112294668A (zh) * | 2020-06-30 | 2021-02-02 | 西安博和医疗科技有限公司 | 透明质酸注射液 |
WO2022090897A1 (en) * | 2020-10-26 | 2022-05-05 | Innate S.R.L. | Injectable composition and use of said composition |
Non-Patent Citations (4)
Title |
---|
"Degradation of hyaluronic acid-Kinetic study and thermodynamics", EUR. POLYM. J, vol. 32, no. 8, 1996, pages 1011 - 1014 |
KATRINA L BOGAN ET AL: "Nicotinic Acid, Nicotinamide, and Nicotinamide Riboside: A Molecular Evaluation of NAD + Precursor Vitamins in Human Nutrition", ANNUAL REVIEW OF NUTRITION., vol. 28, no. 1, 1 August 2008 (2008-08-01), US, pages 115 - 130, XP055461560, ISSN: 0199-9885, DOI: 10.1146/annurev.nutr.28.061807.155443 * |
MCCARTY M F ET AL: "NIACINAMIDE THERAPY FOR OSTEOARTHRITIS - DOES IT INHIBIT NITRIC OXIDE SYNTHASE INDUCTION BY INTERLEUKIN-1 IN CHONDROCYTES?", MEDICAL HYPOTHESES, EDEN PRESS, PENRITH, US, vol. 53, no. 4, 1 October 1999 (1999-10-01), pages 350 - 360, XP002901806, ISSN: 0306-9877, DOI: 10.1054/MEHY.1998.0792 * |
MOETAZ EL-DOMYATI ET AL: "Efficacy of mesotherapy in facial rejuvenation: a histological and immunohistochemical evaluation", INTERNATIONAL JOURNAL OF DERMATOLOGY, WILEY-BLACKWELL PUBLISHING LTD, UK, vol. 51, no. 8, 12 July 2012 (2012-07-12), pages 913 - 919, XP071189531, ISSN: 0011-9059, DOI: 10.1111/J.1365-4632.2011.05184.X * |
Also Published As
Publication number | Publication date |
---|---|
DE102021126946A1 (de) | 2023-04-20 |
EP4392042A1 (de) | 2024-07-03 |
CA3233718A1 (en) | 2023-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE1792346C3 (de) | Pharmazeutisches Präparat für die Behandlung von degenerativen Gelenkerkrankungen | |
DE69731386T2 (de) | Verfahren zur behandlung von asthma mit o-desulfatisiertem heparin | |
EP2358373B1 (de) | Injizierbare polydesoxyribonukleotidzusammensetzung zur behandlung osteoartikulärer krankheiten | |
WO2008071245A1 (de) | Pharmazeutische zubereitung für die behandlung entzündlicher erkrankungen des urogenitaltraktes | |
DE10053053A1 (de) | Pharmazeutische Formulierungen zur Hemmung von entzündlichen Arthritiden | |
WO1993002699A1 (de) | Verwendung von kollagen zur behandlung von degenerativen gelenkprozessen | |
DE69003906T2 (de) | Triacetin enthaltende, langwirkende injizierbare Zusammensetzungen. | |
DE60038118T2 (de) | Formulierungen von wachstumshormonen | |
DE60221227T2 (de) | Xanthangummi enthaltende reepithelialisierende pharmazeutische Zubereitungen | |
EP2879660A1 (de) | Resiniferatoxin-lösung | |
DE3876334T2 (de) | Pharmazeutische zubereitung zur behandlung von gelenkentartung. | |
EP0856312A1 (de) | Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten | |
DE68926746T2 (de) | Auf phosphozucker basierende antientzündliche und/oder immunitätsunterdrückende arzneimittel | |
WO2009021526A1 (de) | Hyaluronsäuredispersion, herstellung und anwendung | |
WO2023066856A1 (de) | Injektionsbehälter, befüllt mit einer wasserhaltigen, injizierbaren zusammensetzung | |
EP0166971A1 (de) | Insulinzubereitungen, Verfahren zu deren Herstellung und deren Verwendung | |
DE2608079A1 (de) | Arzneipraeparat in form eines trockenpraeparats zur herstellung von injektionen | |
DE202012007199U1 (de) | Intrathekale pharmazeutische Baclofen-Dosierungsformen und dazugehöriges Abgabesystem | |
DE60220766T2 (de) | Verwendung eines eine oxaliplatinlösung beinhaltenden fläschchens | |
AT395533B (de) | Verfahren zur herstellung einer pharmazeutischen, parenteralen dosiseinheit von na-piperacillin | |
DE60036790T2 (de) | Verwendung von e5564 zur behandlung von sepsis durch intravenöse infusion | |
Kaiser | Gelenkpunktion und-injektion-Die Geschichte. | |
DE102020100145B4 (de) | Fertigspritze mit Zusammensetzung zur Behandlung einer entzündlichen Gelenkerkrankung | |
EP3400951B1 (de) | Blaseninstillationszusammensetzung enthaltend chondoitinsulfat (4,5 mg/ml), hyaluronsäure (16 mg/ml) und phosphatpuffer (ph 6,1 bis 7,9) mit erhöhter lagerstabiliät zur behandlung von cystitis | |
Vagts et al. | Einsatz von 2% igem hyperbarem Prilocain zur Spinalanästhesie. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22808622 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022808622 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3233718 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2401002348 Country of ref document: TH |
|
ENP | Entry into the national phase |
Ref document number: 2022808622 Country of ref document: EP Effective date: 20240327 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112024007475 Country of ref document: BR |